Gan & Lee Pharmaceutical

Executive Summary

Gan & Lee Pharmaceutical is a fully integrated biopharmaceutical company based in Beijing, China, specializing in the research, development, and manufacturing of biosynthetic insulin analogs and metabolic disease therapies. Founded in 1998, it has become a leading Chinese manufacturer of insulin and delivery devices, catering to the growing demand for diabetes care domestically and globally. As a commercial-stage public company with over 1,000 employees, Gan & Lee leverages its proprietary recombinant DNA technology and production scale to compete in the insulin market, which is dominated by a few global players. The company's focus on biosimilar insulins and novel formulations positions it to capture market share in China's price-sensitive healthcare environment.

Upcoming Catalysts (preview)

• Q4 2026Potential FDA approval for insulin glargine (GL-3003) in the US60% success
• Q2 2026Inclusion in China's national volume-based procurement (VBP) for insulin products80% success
• Q3 2026Launch of next-generation GLP-1 receptor agonist candidate into Phase 3 trials70% success